© 2000 American Heart Association, Inc.
Thrombosis |
Expression, Localization, and Activity of Tissue Factor Pathway Inhibitor in Normal and Atherosclerotic Human Vessels
From the Vascular Biology Laboratory, Thrombosis Research Institute, London, and the Department of Cardiac Medicine (N.J.S.), NHLI, Imperial College, London, UK.
Correspondence to Dr Florea Lupu, Vascular Biology Laboratory, Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, Chelsea, London SW3 6LR, UK. E-mail flupu{at}tri-london.ac.uk
Abstract—Tissue factor (TF) pathway inhibitor (TFPI) is the major downregulator of the procoagulant activity of the TF–factor VIIa (FVIIa) complex (TF · FVII). The active TF present in the atherosclerotic vessel wall is proposed to be responsible for the major complication of primary atherosclerosis, namely, acute thrombosis after plaque rupture, but our knowledge of the sites of TFPI expression in relation to TF remains fragmentary. The aim of this study was to investigate the expression, localization, and activity of TFPI and its relation to the activity and distribution of TF in the normal and atherosclerotic vessel wall. We applied a novel approach in which serial cross sections of human vascular segments were used to perform a complete set of assays: immunolabeling for TFPI and/or TF, in situ hybridization for the expression of TFPI mRNA, ELISA for the determination of TFPI antigen, and functional assay for the activity of TFPI and TF. In healthy vessels, TFPI protein and mRNA are present in luminal and microvascular endothelial cells (ECs) and in the medial smooth muscle cells (SMCs). In atherosclerotic vessels, TFPI protein and mRNA frequently colocalized with TF in ECs overlying the plaque and in microvessels, as well as in the medial and neointimal SMCs, and in macrophages and T cells in areas surrounding the necrotic core. At the ultrastructural level, immunogold electron microscopy confirmed the localization of TFPI in ECs, macrophages/foam cells, and SMCs. In ECs and SMCs, the gold particles decorated the plasmalemma proper and the caveolae. ELISA on cross sections revealed that atherosclerotic tissues contain more TFPI than do the healthy vessels. TFPI was functionally active against TF · FVIIa-induced coagulation, and its activity was higher in those tissues that display less TF. The largest amount of TFPI and TF were detected in complicated arterial plaques. By immunofluorescence, TFPI colocalized with platelet- and fibrin-rich areas within the organized thrombi. Atherosclerotic vessel sections promote activation of factor X, which is dependent on the presence of TF and enhanced by preincubation of the sections with anti-TFPI IgG. Taken altogether, our results suggest that TFPI is largely expressed in the normal vessel wall and enhanced in the atherosclerotic vessel, in a manner suggesting a significant role of TFPI in the regulation of TF activity.
Key Words: atherosclerosis • tissue factor pathway inhibitor • anticoagulant activity • immunocytochemistry • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  S. W. Waldo, Y. Li, C. Buono, B. Zhao, E. M. Billings, J. Chang, and H. S. Kruth Heterogeneity of Human Macrophages in Culture and in Atherosclerotic Plaques Am. J. Pathol., April 1, 2008; 172(4): 1112 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Okorie, W. S. Denney, M. S. Chatterjee, K. B. Neeves, and S. L. Diamond Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow Blood, April 1, 2008; 111(7): 3507 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T.B. Crawley and D. A. Lane The Haemostatic Role of Tissue Factor Pathway Inhibitor Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tang, L. Ivanciu, N. Popescu, G. Peer, E. Hack, C. Lupu, F. B. Taylor Jr, and F. Lupu Sepsis-Induced Coagulation in the Baboon Lung Is Associated with Decreased Tissue Factor Pathway Inhibitor Am. J. Pathol., September 1, 2007; 171(3): 1066 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, S. Mangan, and P. Clancy Effects of Peroxisome Proliferator-Activated Receptor Ligands in Modulating Tissue Factor and Tissue Factor Pathway Inhibitor in Acutely Symptomatic Carotid Atheromas Stroke, May 1, 2007; 38(5): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Aird Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms Circ. Res., February 2, 2007; 100(2): 158 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Oynebraten, N. Barois, K. Hagelsteen, F.-E. Johansen, O. Bakke, and G. Haraldsen Characterization of a Novel Chemokine-Containing Storage Granule in Endothelial Cells: Evidence for Preferential Exocytosis Mediated by Protein Kinase A and Diacylglycerol J. Immunol., October 15, 2005; 175(8): 5358 - 5369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lupu, A. D. Westmuckett, G. Peer, L. Ivanciu, H. Zhu, F. B. Taylor Jr., and F. Lupu Tissue Factor-Dependent Coagulation Is Preferentially Up-Regulated within Arterial Branching Areas in a Baboon Model of Escherichia coli Sepsis Am. J. Pathol., October 1, 2005; 167(4): 1161 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lupu, X. Hu, and F. Lupu Caveolin-1 Enhances Tissue Factor Pathway Inhibitor Exposure and Function on the Cell Surface J. Biol. Chem., June 10, 2005; 280(23): 22308 - 22317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Piro and G. J. Broze Jr Role for the Kunitz-3 Domain of Tissue Factor Pathway Inhibitor-{alpha} in Cell Surface Binding Circulation, December 7, 2004; 110(23): 3567 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Golino, A. Ravera, M. Ragni, P. Cirillo, O. Piro, and M. Chiariello Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes Circulation, December 9, 2003; 108(23): 2864 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, O. Piro, L. Lu, and G. J. Broze Jr Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway Inhibitor Circulation, August 5, 2003; 108(5): 623 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Razani, S. E. Woodman, and M. P. Lisanti Caveolae: From Cell Biology to Animal Physiology Pharmacol. Rev., September 1, 2002; 54(3): 431 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T.B. Crawley, D. A. Goulding, V. Ferreira, N. J. Severs, and F. Lupu Expression and Localization of Tissue Factor Pathway Inhibitor-2 in Normal and Atherosclerotic Human Vessels Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 218 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ott, V. Malcouvier, A. Schomig, and F.-J. Neumann Proteolysis of Tissue Factor Pathway Inhibitor-1 by Thrombolysis in Acute Myocardial Infarction Circulation, January 22, 2002; 105(3): 279 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jander, M. Sitzer, A. Wendt, M. Schroeter, M. Buchkremer, M. Siebler, W. Muller, W. Sandmann, and G. Stoll Expression of Tissue Factor in High-Grade Carotid Artery Stenosis : Association With Plaque Destabilization Stroke, April 1, 2001; 32(4): 850 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|